Horizon and partners fill bioproduction void
A band of biotech brothers in Cambridge has moved to plug a serious gap in the bioproduction process and hand a major boost to global drug makers.
Horizon Discovery, the Sanger Institute and Eagle Genomics have joined forces for the initiative.
Over the past 30 years, the pharmaceutical industry has substantively redesigned every part of the bioproduction process, considerably improving productivity.
However the CHO cell itself, arguably the greatest potential source of efficiency improvements, has remained largely unchanged. The CHO genome was first sequenced in 2011 but the current annotation is not suitable for whole-genome screening. Together with licensing terms that restrict modification of the cells, this has meant that progress in cell-line improvement has been slow.
This has been a source of considerable frustration among drug manufacturers, as there has been increasing interest in improving productivity through cell-line innovation since the emergence of gene-editing tools such as CRISPR.
Now Horizon, Sanger and Eagle Genomics have established a high-quality sequence map based on Horizon’s GS Knock-Out CHO K1 cell line.
By releasing this sequence into the public domain, Horizon hopes to enable genuine quality-by-design in bioproduction cell-line development, through the widespread ability to identify genes that, if modified, could improve the phenotype of interest.
The sequence is being made available publicly via the Ensembl website at EMBL-EBI, to serve the community as a resource to drive research and innovation in bioproduction not only at Horizon but also across the industry.
Horizon’s GS Knock-Out CHO K1 cell line was chosen as the basis for this project as it is manufacturing-ready,and licences come with the right to modify the cells, which is highly unusual among commercially available GS CHO KO cells.
The use of Horizon’s cells alongside the public sequence thereby provides an ideal base and dataset to enable screening that can provide immediately actionable results.
The public sequence can also be applied to any other CHO cell line; however, additional validation of sequence may be required to confirm the cell line being used does not differ in any meaningful way from the public sequence.
The sequencing project was undertaken as part of the Biocatalyst Funding awarded jointly to Horizon, University of Manchester and the Centre for Process Innovation (CPI).
The Biocatalyst Funded project is focused primarily on large-scale gene editing to improve CHO host performance, which in turn required specific high-resolution sequencing of the Horizon GS knockout CHO host. To achieve this, Horizon collaborated with the Sanger Institute to achieve the detailed genome sequencing needed and chose Eagle Genomics to deliver the complex annotation of the genome assembly.
This sequence empowers Horizon’s continuous innovation process, supporting the identification of targets that may lead to future iterations of the cell line. Additionally, Horizon has developed a range of services to directly support customers’ internal efficiency improvement efforts.
Dr Darrin Disley (pictured), CEO of Horizon Discovery, said: “This programme, and the subsequent public release of our GS Knock-Out CHO K1 cell line, further reinforces Horizon’s leadership position in bioproduction and distinctive ability to drive innovation, both internally and industry-wide.
“Horizon’s open philosophy on sequence data, alongside our disruptive cell line licensing model, continues to challenge the industry and push the boundaries in bioproduction.
“It is our belief that greater innovation in the bioproduction space ultimately benefits the patient through enabling the commercial manufacture of therapeutics that would not be possible with existing solutions.
“Eagle Genomics has proven the ideal partner for this project and we look forward to collaborating with them on similar ventures in the future.”
Abel Ureta-Vidal, CEO of Eagle Genomics, added: “Genome assembly and annotation are essential to genomic data innovation and to drive product development.
“Unfortunately, generating a CHO reference genome of sufficient quality for applications like genome engineering has been notoriously difficult due to aneuploidy and complex chromosome rearrangements of the cell line.
“Our analysis of high-quality source data using multiple bioinformatics methods in a robust QC framework was able however to produce a reference that materially improved on previous efforts.
“It is gratifying that now, for the first time, a commercially available bioproduction cell line can be directly paired with its detailed reference genome and we believe this will be vital to unlocking the potential of the cell lines.”